drugset / Trial / NCT00914368

Tailoring Of Platelet Inhibition to Avoid Stent Thrombosis

NCT00914368

Phase 2 Completed 450 enrolled Uppsala University
Non-randomizedParallel-groupOpen-labelScreening

Summary

The primary objective of this study is to establish a cut off level of platelet inhibition that separates patients with or without previous stent occlusion with acute clinical onset while on aspirin and clopidogrel treatment within 6 months after coronary stenting for coronary artery disease.

Timeline

Start
2009-01
Primary completion
2010-03
Completion
2010-03

Drugs

EvaluationDrugModalityDoseRoute
Comparator Clopidogrel Small molecule 75 mg